None listed
Conditions
Interventions
Drug : After surgery, the test group dilutes Amburofen inj. 800mg/8ml (ibuprofen) to more than 200mL of intravenous fluid for more than 30 minutes, intravenously administered at intervals of 6 hours.
Sponsors
The Catholic University of Korea, Seoul St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have undergone selective cholecystic surgery for cholelithiasis, chronic cholecystitis, cholecystic polyp, and cholecystic adenomyoma
Exclusion criteria
Exclusion criteria: ? acute cholecystitis ? gallbladder cancer ? Gallbladder inflammation with a gallbladder thickness of 4mm or more on CT or ultrasound ? gallbladder inflammation that causes adhesion to surrounding organs ? a pregnant woman or a lactating woman ? A person who performs surgery simultaneously due to other organ diseases ? People with immunosuppressive and hemorrhagic tendencies ? A person who has undergone percutaneous gallbladder drainage (PTGBD) before alcohol ? A person who is required to install a drain pipe during surgery ? Participants in other clinical trials within 3 months prior to screening ? Other persons deemed unfit by the tester to participate in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| postoperative pain score | — |
Secondary
| Measure | Time frame |
|---|---|
| incidence of postoperative infection-related complications;incidence of postoperative infection-related complications | — |
Countries
Korea, Republic of
Contacts
Public ContactTaeho Hong
The Catholic University of Korea, Seoul St. Mary's Hospital
Outcome results
None listed